Immune Cell Phenotypes Associated with Successful Response to 2 Weeks of a Novel Non-Nucleoside Inhibitor CDI-31244 Concurrent with 6 Weeks of Sofosbuvir/Velpatasvir in Subjects with Chronic Hepatitis C Genotype 1 Infection.

Alip Ghosh, PhD1; Sara Romani2; Afua Ntem-Mensah, MD1; Ameer Abutaleb, MD2; Lydiah Mutumbi, RN1; Ka Wing Lam1; Maria Luz Pascual, MD3; Sam Lee, PhD1; Shyam Kotttilil, MD, PhD1; Joel V. Chua, MD1; Bhawna Poonia, PhD1

1 Institute of Human Virology, School of Medicine, University of Maryland, Baltimore, MD. 21201. 2 Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA. 3 Cocrystal Pharma, Inc. Bothell, Washington, USA.

Background

The high cost of currently approved combination direct-acting antiviral (DAA) therapy of 8- and 12-weeks duration is a major barrier to the treatment of chronic hepatitis C (HCV) globally. Shorter duration therapy that maintains high cure rates of current therapy could reduce cost and improve adherence. Pretreatment identification of biomarkers that are associated with successful response to shorter duration therapy could aid this goal. The frequencies of circulating T cell and natural killer (NK) cell subsets have been shown to be associated with an ability to achieve either rapid virologic response or clearance using 12 weeks of DAA therapy.1,2

Results

Eight of 12 (67%) patients achieved SVR12 and SVR24. Patients that achieved SVR had significantly higher frequencies of terminally differentiated effector memory CD8+ T cells compared with those who relapsed at both baseline and at end-of-6-week treatment (Figure 1). At the same time, the frequency of naïve CD8+ T cells was lower while the frequency of effector memory CD8+ T cells was higher in SVR patients; however, these differences were not statistically significant. NK cell cytotoxic phenotypes determined by measuring expression of TRAIL and CD107a also did not differ between SVR and relapse patients, unlike another study that evaluated a different regimen for 12 weeks.2

Subject Demographics

We investigated the association of specific immune cell biomarkers with sustained virologic response (SVR) or relapse in 12 treatment-naïve patients with chronic HCV genotype 1 infection without cirrhosis enrolled in a single center, phase 2a study to evaluate treatment with 2 weeks of a novel non-nucleoside inhibitor CDI-31244 (400 mg daily) concurrent with 6 weeks of sofosbuvir/velpatasvir (SOF/VEL) (Clinicaltrials.gov NCT# 03501550). Immunophenotyping with antibody staining and flow cytometry as well as degranulation assays were employed to investigate the frequency of both T cell and NK cell subsets1,2 and their association with response to this regimen.

Method

We investigated the association of specific immune cell biomarkers with sustained virologic response (SVR) or relapse in 12 treatment-naïve patients with chronic HCV genotype 1 infection without cirrhosis enrolled in a single center, phase 2a study to evaluate treatment with 2 weeks of a novel non-nucleoside inhibitor CDI-31244 (400 mg daily) concurrent with 6 weeks of sofosbuvir/velpatasvir (SOF/VEL) (Clinicaltrials.gov NCT# 03501550). Immunophenotyping with antibody staining and flow cytometry as well as degranulation assays were employed to investigate the frequency of both T cell and NK cell subsets1,2 and their association with response to this regimen.

Conclusion

CD8+ effector T cell phenotypes are associated with successful response to the novel NNI CDI-31244 in combination with SOF/VEL in treatment-naïve adults with chronic HCV genotype 1 infection without cirrhosis. Identifying these select patients may be valuable in the development of ultrashort duration HCV therapy.

REFERENCES: